← Donald E. Cutlip

Papers by Donald E. Cutlip

Page 2 · newest first

51. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary StentingJAMA Cardiology · 2017
52. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy)Circulation · 2017
53. Relationship of Albuminuria and Renal Artery Stent OutcomesHypertension · 2016
54. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy StudyCirculation · 2016
55. Type 4a myocardial infarction: Incidence, risk factors, and long‐term outcomesCatheterization and Cardiovascular Interventions · 2016
56. Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL TrialClinical Journal of the American Society of Nephrology · 2016
57. Should We Screen for Coronary Heart Disease in Asymptomatic Persons?Annals of Internal Medicine · 2016
58. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary InterventionJAMA · 2016
59. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy StudyCirculation · 2016
60. Causes of late mortality with dual antiplatelet therapy after coronary stentsEuropean Heart Journal · 2015
61. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principlesEuropean Heart Journal · 2015
62. Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary StentsJAMA · 2015
63. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting StentsNew England Journal of Medicine · 2014
64. Cost‐Effectiveness of Supervised Exercise, Stenting, and Optimal Medical Care for Claudication: Results From the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) TrialJournal of the American Heart Association · 2014
65. Evaluation of long-term clinical and health service outcomes following coronary artery revascularisation in Western Australia (WACARP): a population-based cohort study protocolBMJ Open · 2014
66. Is fibromuscular dysplasia underdiagnosed? A comparison of the prevalence of FMD seen in CORAL trial participants versus a single institution population of renal donor candidatesVascular Medicine · 2014
67. Use of Renin-Angiotensin Inhibitors in People with Renal Artery StenosisClinical Journal of the American Society of Nephrology · 2014
68. Risk Assessment to Predict Arterial and Venous Events in Patients Undergoing Percutaneous Coronary InterventionClinical and Applied Thrombosis/Hemostasis · 2014
69. Stenting and Medical Therapy for Atherosclerotic Renal-Artery StenosisNew England Journal of Medicine · 2013
70. Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: A meta‐analysis and critical examination of current methodologiesCatheterization and Cardiovascular Interventions · 2013
71. Long‐term efficacy and safety of zotarolimus‐eluting stent in patients with diabetes mellitus: Pooled 5‐year results from the ENDEAVOR III and IV trialsCatheterization and Cardiovascular Interventions · 2013
72. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus‐ vs. Paclitaxel‐eluting stents in de novo occlusive lesions in coronary arteries: Five‐year results from the ZOMAXX I trialCatheterization and Cardiovascular Interventions · 2013
73. Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb–IIIa inhibitorsJournal of Cardiovascular Medicine · 2013
74. Nonemergency PCI at Hospitals with or without On-Site Cardiac SurgeryNew England Journal of Medicine · 2013
75. Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE ProgramHeart · 2013
76. Risk Prediction for Adverse Events After Carotid Artery Stenting in Higher Surgical Risk PatientsStroke · 2012
77. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document#EuroIntervention · 2012
78. Repeat Revascularization After Contemporary Percutaneous Coronary InterventionCirculation Cardiovascular Interventions · 2012
79. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus documentJournal of Thoracic and Cardiovascular Surgery · 2012
80. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document†European Heart Journal · 2012
81. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trialsBMJ · 2012
82. Time-related impact of distal embolisation on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperationEuroIntervention · 2012
83. Clinical event committees in coronary stent trials: insights and recommendations based on experience in an unselected study populationEuroIntervention · 2012
84. Periprocedural Myocardial Infarction in a Randomized Trial of Everolimus-Eluting and Paclitaxel-Eluting Coronary StentsCirculation Cardiovascular Interventions · 2012
85. Evidence of Safety and Effectiveness for a Drug-Eluting StentCirculation · 2012
86. Platelet-Mediated Thrombosis and Drug-Eluting StentsCirculation Cardiovascular Interventions · 2011
87. Frequency and impact of bleeding in elective coronary stent clinical trials—Utility of three commonly used definitionsCatheterization and Cardiovascular Interventions · 2011
88. Supervised Exercise Versus Primary Stenting for Claudication Resulting From Aortoiliac Peripheral Artery DiseaseCirculation · 2011
89. Predicting the Restenosis Benefit of Drug-Eluting Versus Bare Metal Stents in Percutaneous Coronary InterventionCirculation · 2011
90. Standardized Bleeding Definitions for Cardiovascular Clinical TrialsCirculation · 2011
91. Myocardial Infarction After Carotid Stenting and EndarterectomyCirculation · 2011
92. The Academic Research Consortium Governance CharterJACC: Cardiovascular Interventions · 2011
93. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research ConsortiumEuropean Heart Journal · 2011
94. Abstract 17234: Blood Pressure Control in Patients with Renal Artery Stenosis, Preliminary Results of the CORAL Clinical TrialCirculation · 2010
95. Carotid Artery Stenting vs Carotid EndarterectomyArchives of Neurology · 2010
96. Predicting Restenosis of Drug-Eluting Stents Placed in Real-World Clinical PracticeCirculation Cardiovascular Interventions · 2010
97. Stenting versus Endarterectomy for Treatment of Carotid-Artery StenosisNew England Journal of Medicine · 2010
98. Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery DiseaseNew England Journal of Medicine · 2010
99. Long-term clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trialEuroIntervention · 2010
100. Five‐year clinical follow‐up after implantation of the endeavor zotarolimus‐eluting stent: ENDEAVOR I, first‐in‐human studyCatheterization and Cardiovascular Interventions · 2009